课题基金 / 基金详情

MECHANISM OF ENZYME INHIBITION BY PHARMACOLOGICAL AGENTS

MECHANISM OF ENZYME INHIBITION BY PHARMACOLOGICAL AGENTS
药理制剂抑制酶的机制
批准号:
2269863
负责人:
JOHN J. COLICELLI
金额:
$6.3万
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-08-01 至 1996-07-31

项目摘要

项目成果

JOHN J. COLICELLI的其他基金

相似基金

相关文献

中文摘要
翻译
此建议的目标是定义一个
英文摘要
The objective of this proposal is to define the interaction between an enzyme and a highly specific competitive inhibitor. The enzyme being studied is a mammalian cAMP-specific isozyme of phosphodiesterase (PDE) that is strongly implicated in learning and memory functions. Inhibitors of this enzyme are pharmacologically useful in the treatment of some human pathologies. The work involves the use of a novel in vivo drug-resistance selection for mutants of a mammalian enzyme expressed in yeast. This reconstitution of a mammalian gene product into yeast cells results in a simplified system and a mechanism for the isolation of rare drug resistant mutants. The selection to be used is designed to isolate mammalian PDE mutants that are incapable of interacting with a competitive inhibitor (rolipram), but are not affected in substrate (cAMP) binding or hydrolysis. This work should lead to a better understanding of the nature of the interaction between a mammalian PDE enzyme and a pharmacologically useful drug. In addition, the methods employed in this research should prove useful in both the design and testing of more potent inhibitors of this enzyme. The methodology will also be extended to the study of other mammalian enzymes. These new techniques could provide an invaluable tool for the analysis of a wide variety of inhibitor-enzyme interactions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Novel Screen for Compounds that Outflank BCR-ABL Drug-Resistance
A Novel Screen for Compounds that Outflank BCR-ABL Drug-Resistance
Mechanism of RIN1 Signaling in Neuronal Plasticity
Mechanism of RIN1 Signaling in Neuronal Plasticity
海外基金